1. Home
  2. DYNX vs VNDA Comparison

DYNX vs VNDA Comparison

Compare DYNX & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DYNX
  • VNDA
  • Stock Information
  • Founded
  • DYNX 2024
  • VNDA 2002
  • Country
  • DYNX United States
  • VNDA United States
  • Employees
  • DYNX N/A
  • VNDA N/A
  • Industry
  • DYNX
  • VNDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • DYNX
  • VNDA Health Care
  • Exchange
  • DYNX NYSE
  • VNDA Nasdaq
  • Market Cap
  • DYNX 221.3M
  • VNDA 261.7M
  • IPO Year
  • DYNX 2024
  • VNDA 2006
  • Fundamental
  • Price
  • DYNX N/A
  • VNDA $4.97
  • Analyst Decision
  • DYNX
  • VNDA Strong Buy
  • Analyst Count
  • DYNX 0
  • VNDA 3
  • Target Price
  • DYNX N/A
  • VNDA $15.33
  • AVG Volume (30 Days)
  • DYNX 20.9K
  • VNDA 417.8K
  • Earning Date
  • DYNX 01-01-0001
  • VNDA 07-30-2025
  • Dividend Yield
  • DYNX N/A
  • VNDA N/A
  • EPS Growth
  • DYNX N/A
  • VNDA N/A
  • EPS
  • DYNX N/A
  • VNDA N/A
  • Revenue
  • DYNX N/A
  • VNDA $201,351,000.00
  • Revenue This Year
  • DYNX N/A
  • VNDA $16.86
  • Revenue Next Year
  • DYNX N/A
  • VNDA $39.78
  • P/E Ratio
  • DYNX N/A
  • VNDA N/A
  • Revenue Growth
  • DYNX N/A
  • VNDA 13.37
  • 52 Week Low
  • DYNX $9.78
  • VNDA $3.81
  • 52 Week High
  • DYNX $10.48
  • VNDA $6.37
  • Technical
  • Relative Strength Index (RSI)
  • DYNX N/A
  • VNDA 67.29
  • Support Level
  • DYNX N/A
  • VNDA $4.66
  • Resistance Level
  • DYNX N/A
  • VNDA $4.95
  • Average True Range (ATR)
  • DYNX 0.00
  • VNDA 0.15
  • MACD
  • DYNX 0.00
  • VNDA 0.03
  • Stochastic Oscillator
  • DYNX 0.00
  • VNDA 89.39

About DYNX DYNAMIX CORP

Dynamix Corp is a blank check company.

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Share on Social Networks: